Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of LIB-01 in Healthy Participants
NCT06324006Phase 1Completed
- Sponsor
- Dicot Pharma AB
- Start
- Aug 2023
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in erectile dysfunction (ED) comparing LIB-01 with Placebo (2 arms). Primary endpoints: Incidence of treatment-emergent adverse events as assessed by CTCAE following a single oral dose at 14 days, Changes in vital signs following a single oral dose at 14 days and 4 more. Started Aug 2023; status: completed.
02
Drugs
LIB-01
03
Conditions
erectile dysfunction (ED)
Beyond the preview
Go deeper on NCT06324006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06324006.